Virtual, Interactive Conference

Saturday, March 20, 2021

8:00 AM - 4:45 PM ET

PER’s practice changing 6th Annual School of Gastrointestinal Oncology^® (SOGO™) is a 1-day multidisciplinary educational conference, revolutionizing the presentation of emerging therapies and evolving standards of care in the management of patients with gastrointestinal (GI) cancer.

Led by world-renowned experts John L. Marshall, MD, and Michael A. Choti, MD, MBA, FACS, this symposium, now in its sixth year, will provide you with the tools you need to personalize care for each patient with GI cancer. The program will feature presentations on locoregional treatment of GI cancers and management of advanced GI cancers, as well as case-based discussions on multidisciplinary, real-world management of GI cancers. This program is designed to match your learning interests, with updates on the latest clinical trial data, current and emerging treatment strategies, and case-based lectures by expert faculty with a focus on the practical application of knowledge to the complex care scenarios encountered in contemporary practice settings. Physicians’ Education Resource^® (PER^®) is committed to deliver an interactive meeting that fosters discussion, exchange of ideas, best practices, and multidisciplinary collaboration in the clinic.

Physicians' Education Resource^®’s top priority is ensuring the safety and security of our attendees, staff, and operational personnel. We are dedicated to remaining informed about the ongoing COVID-19 pandemic at the global and local levels. As we develop the programming for this activity, Physicians' Education Resource^® will follow the guidelines to optimize health and conditions for attendees during the event. Ongoing updates on Physicians' Education Resource^®'s plans related to this event, including education and programming, will continue to be available at www.gotoper.com/conferences/sogo/meetings/6th-annual-school-of-gastrointestinal-oncology. Please note attendance at any public event increases the risk of contracting COVID-19 or other airborne illness, and attendees assume all risk associated with attendance. Any attendees who feel ill, regardless of their symptoms, should not attend this event.

• Implement protocols to support best practice treatment selection for your patients with GI cancer
• Gain awareness of the clinical trials evaluating current and emerging agents for GI cancer treatment that may affect your practice in the future
• Learn how the experts and your peers are managing challenging patient cases
• Ask the experts about best practices for mitigating adverse events related to treatment of GI cancers

This activity is supported by educational grants from AstraZeneca; BMS - Bristol-Myers Squibb - Lawrenceville; Daiichi Sankyo, Inc.; Exelixis, Inc.; Genomic Health, Inc.; Incyte Corporation; Merck & Co., Inc.; Pfizer Inc., and Taiho Oncology, Inc.

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 7.25 Contact Hours.

This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, gastroenterologists, and hepatologists who are interested in the treatment of GI cancers. Nurse practitioners, physician assistants, nurses, pathologists, pharmacists, and other healthcare professionals involved in the treatment and management of patients with GI cancers are invited to attend.

Upon completion of this activity, participants will be able to:

• Use molecular markers to inform diagnosis and provide treatment guidance for patients with GI cancer
• Determine a comprehensive treatment plan for patients with early-stage GI cancer in the context of multidisciplinary collaboration among radiation oncologists, surgical oncologists, and medical oncologists
• Optimize current treatment strategies based on guideline updates for patients with advanced GI cancer
• Incorporate novel treatment strategies into clinical practice to improve the outcomes of patients with GI cancer
• Assess management strategies to proactively mitigate treatment-related adverse events experienced by patients with GI cancer